[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580914":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":24,"responsibleParty":43,"collaborators":45,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":26,"whyStopped":19,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"AI Intervention","Patients will undergo fundus photography screening using artificial intelligence-assisted diagnostic software (VeriSee). Ophthalmologists will independently interpret the same images, and the results will be compared with those generated by the AI.",[12,13],"Other: The VeriSee AI-assisted diagnostic system","Other: Data collection from the patient's clinical history",[15,20],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"The VeriSee AI-assisted diagnostic system","VeriSee AMD, VeriSee DR, and VeriSee GLC are AI-based medical software devices designed for screening age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, respectively. These systems utilize advanced AI algorithms to analyze color fundus photography images for disease assessment. By installing the software on a computer, the system can evaluate image quality, predict disease conditions, and instantly provide results to clinical physicians, serving as a diagnostic aid.",[9],null,{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":19},"Data collection from the patient's clinical history","Data collection from the patient's clinical history was conducted because the VeriSee AI-assisted diagnostic system was not used.",[9],[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":28,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Taipei","Taiwan","100225","TW",{"type":32,"coordinates":33},"Point",[34,35],121.52639,25.05306,{"lat":35,"lon":34},[38],{"name":39,"role":40,"phone":41,"phoneExt":19,"email":42},"Yi-Ting Hsieh, Medical Doctor","CONTACT","+886-2-2312-3456 ext. 265018","ythyth@gmail.com",{"type":44,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[46,48,50],{"name":47,"class":6},"Fu Jen Catholic University Hospital",{"name":49,"class":6},"Min-Sheng General Hospital",{"name":51,"class":52},"Ministry of Health and Welfare, Taiwan","OTHER_GOV","100580914","effectiveness-and-cost-effectiveness-evaluations-of-ai-assisted-diagnostic-software-verisee-for-ophthalmic-disease-screening-100580914",false,"NCT06843499","Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening","Inclusion Criteria:\n\n* VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.\n* VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.\n\nExclusion Criteria:\n\n* The patient does not agree to participate in the trial or is unable to provide informed consent.","ALL","20 Years",{"count":62,"type":63},1000,"ESTIMATED","INTERVENTIONAL",[66],"NA","This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.",[69,70],"Age-Related Macular Degeneration (AMD)","Diabetic Retinopathy (DR)",[72,73,74,75,76],"Artificial Intelligence","imaging analysis","disease diagnosis","macular degeneration","diabetic retinopathy","2025-06-17",{"date":79,"type":80},"2025-06-22","ACTUAL",{"date":82,"type":80},"2025-06-02",{"date":84,"type":63},"2027-12-31",{"name":5,"class":6},1]